Yearly Archives: 2010

­

Quark Pharmaceuticals to Present Phase I Data for QPI-1002 in Delayed Graft Function at American Transplant Congress

May 4th, 2010|

FREMONT, Calif., May 4, 2010 – Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that data from the Phase I QPI-1002 (I5NP) DGF Study (NCT#00802347) will be presented at the 2010 American Transplant Congress, taking place May 1-5 in San Diego, California. QPI-1002, the first systemically administered siRNA drug […]

Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007

March 1st, 2010|

FREMONT, Calif., March 1st, 2010 – Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007. This drug candidate, having a proprietary siRNA structure, is being developed for the treatment of non-arteritic […]

FDA Grants Orphan Drug Status for Quark’s QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients

February 16th, 2010|

FREMONT, Calif., February 16, 2010 – Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today that the US FDA has granted orphan drug designation for QPI-1002 (also referred to as “I5NP”), a synthetic siRNA targeting p53 mRNA for the prophylaxis of delayed graft function (DGF) in kidney transplant […]

Quark Pharmaceuticals Poised to Advance Clinical Studies of QPI-1002

January 5th, 2010|

First Synthetic siRNA Administered Systemically to Humans for the Prophylaxis of Acute Kidney Injury and Delayed Graft Function

FREMONT, Calif., Jan. 5  Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that the independent Data Safety Monitoring Board (“DSMB”) recommended that QPI-1002 (I5NP) continue on to the next phase of clinical […]